Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZK2401
- Development stage
- Phase 1
- Lead developer
- Lee's Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ZK2401 is a recombinant humanized bispecific antibody developed by Lee's Pharmaceutical for the treatment of advanced solid tumors. It is designed to simultaneously target Programmed Death-Ligand 1 (PD-L1) and 4-1BB (CD137). The molecule functions by blocking the immunosuppressive PD-1/PD-L1 checkpoint while providing a localized costimulatory signal through 4-1BB to activate tumor-infiltrating T cells. This dual-targeting approach aims to improve therapeutic efficacy and reduce the systemic toxicities often associated with systemic 4-1BB agonists. ZK2401 is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and preliminary efficacy in patients with solid tumors.
- Other names
- anti-PD-L1/4-1BB bispecific antibody
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on ZK2401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZK2401.